A blood eosinophil value of <0.144 × 109/L on admission or <2 percent is predictive of a longer hospital length of stay (LOS) among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), suggests a study.
Chronic obstructive pulmonary disease (COPD) patients with comorbid chronic cough appear to exhibit a more severe disease in terms of accompanying respiratory symptoms and healthcare utilization, lung function, and inflammation in blood, according to a study.
In chronic obstructive pulmonary disease (COPD) patients initiating inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, both budesonide/formoterol (FOR) dry-powder inhalers and beclomethasone/FOR metered-dose inhalers pose lower risks of severe pneumonia and severe adverse events compared with fluticasone/salmeterol delivered using the same type of inhaler, as reported in a recent study.
Exposure to inhaled corticosteroid therapy for chronic obstructive pulmonary disease (COPD) in the long term may be detrimental to patients, being associated with elevated risks of diabetes, its progression and osteoporosis, as shown in a study.
Patients with chronic obstructive pulmonary disease (COPD) who initiate treatment with inhaled corticosteroids (ICS) may have an elevated risk of developing type 2 diabetes mellitus (T2DM), according to a matched cohort study.
Nasal high flow (NHF) during exercise has failed to boost endurance time in patients with chronic obstructive pulmonary disease (COPD) who are recovering from acute exacerbation, as shown in a recent study.
Treatment without antibiotic medication does not appear to be inferior to moxifloxacin therapy as regards treatment failure or length of stay (LOS) among patients with chronic obstructive pulmonary disease (COPD) requiring hospitalization for nonpurulent exacerbation, according to the results of a study presented at the European Respiratory Society (ERS) International Congress 2019.
The use of single-inhaler triple therapy yields meaningful improvements across a range of chronic obstructive pulmonary disease (COPD) endpoints over time compared with dual therapies, according to data from the IMPACT* trial presented at the 2019 European Respiratory Society (ERS) International Congress.
With the release of the latest interim efficacy results for ChAdOx1 nCoV-19, the adenovirus-vectored vaccine against COVID-19 is inching a step closer towards regulatory approval — and eventually, widespread use that will hopefully put an end to the relentless carnage by the pandemic.